33:@0.890196:0.957873:0.907378:0.957873:0.907378:0.938882:0.890196:0.938882:0.008591:0.008591
AN ORGANOID PLATFORM FOR OVARIAN CANCER CAPTURES INTRA- AND INTERPATIENT HETEROGENEITY:@0.285725:0.064721:0.882540:0.064721:0.882540:0.047603:0.285725:0.047603:0.007919:0.008759:0.002988:0.008442:0.008311:0.008292:0.007919:0.008759:0.008442:0.003511:0.008423:0.002988:0.008050:0.006481:0.007095:0.006387:0.006593:0.008442:0.008423:0.011112:0.002988:0.006593:0.008442:0.008423:0.002988:0.008328:0.006966:0.007919:0.008423:0.003511:0.007919:0.008759:0.002988:0.008180:0.007919:0.008759:0.008255:0.006985:0.008423:0.002988:0.008178:0.007919:0.007975:0.006387:0.008367:0.008423:0.006873:0.007807:0.002988:0.003511:0.008759:0.006387:0.008423:0.007543:0.005155:0.002801:0.007919:0.008759:0.008423:0.002988:0.003511:0.008759:0.006387:0.006985:0.008423:0.007581:0.007099:0.006387:0.003511:0.006985:0.008759:0.006199:0.002988:0.008685:0.006985:0.006387:0.006985:0.008311:0.008442:0.008404:0.006985:0.008759:0.006985:0.003511:0.006387:0.007732
2:@0.941813:0.247137:0.963291:0.247137:0.963291:0.199659:0.941813:0.199659:0.021478
pensed into 384-well plates pre-coated with BME. A cell viability assay was performed :@0.147059:0.121273:0.886462:0.121273:0.886462:0.100900:0.147059:0.100900:0.011505:0.009039:0.011619:0.007875:0.009108:0.011391:0.005330:0.005615:0.011391:0.006209:0.011048:0.005330:0.010432:0.010432:0.010432:0.007533:0.014516:0.008948:0.005387:0.005250:0.005330:0.011162:0.005433:0.008811:0.006209:0.009039:0.007670:0.005330:0.011073:0.007442:0.009039:0.007533:0.008994:0.011137:0.008811:0.006209:0.009108:0.011391:0.005330:0.014723:0.005273:0.006620:0.011459:0.005330:0.012646:0.019608:0.012098:0.004497:0.005330:0.014929:0.005330:0.008994:0.008948:0.005387:0.005250:0.005330:0.009838:0.005798:0.009108:0.010820:0.005752:0.005250:0.005273:0.006437:0.009724:0.005330:0.009291:0.007533:0.007944:0.008925:0.009724:0.005330:0.014723:0.009291:0.007670:0.005330:0.011505:0.009039:0.007807:0.006026:0.010843:0.007807:0.017485:0.009108:0.011391:0.004109
5 days after the drugs were added and organoid drug sensitivity was represented by the :@0.147059:0.141852:0.886393:0.141852:0.886393:0.121479:0.147059:0.121479:0.010432:0.004908:0.011573:0.008925:0.009724:0.007670:0.004908:0.009085:0.006197:0.005969:0.009039:0.007807:0.004908:0.006620:0.011299:0.009039:0.004908:0.011391:0.007967:0.011413:0.009724:0.007670:0.004908:0.014518:0.009039:0.007442:0.009039:0.004908:0.009291:0.011322:0.011322:0.009108:0.011391:0.004908:0.009085:0.011598:0.011391:0.004908:0.010843:0.007624:0.009861:0.009085:0.011596:0.010843:0.005547:0.011391:0.004908:0.011391:0.007967:0.011413:0.009861:0.004908:0.007875:0.009039:0.011619:0.007601:0.005273:0.006437:0.005545:0.009838:0.005273:0.006437:0.009724:0.004908:0.014723:0.009291:0.007670:0.004908:0.007442:0.009128:0.011071:0.007444:0.009039:0.007873:0.009039:0.011391:0.006209:0.009108:0.011391:0.004908:0.010843:0.009724:0.004908:0.006620:0.011299:0.009039:0.004109
average area under the dose–response curve (AUC) of two technical replicates . Assay :@0.147059:0.162431:0.886471:0.162431:0.886471:0.142058:0.147059:0.142058:0.008925:0.009633:0.009039:0.007898:0.009199:0.009656:0.009039:0.004611:0.009085:0.007442:0.009291:0.009291:0.004611:0.011413:0.011596:0.011324:0.009039:0.007807:0.004611:0.006620:0.011299:0.009039:0.004611:0.011322:0.010957:0.007875:0.009039:0.011801:0.007442:0.009039:0.007510:0.011502:0.010845:0.011619:0.007873:0.009039:0.004611:0.009106:0.011413:0.008400:0.009633:0.009039:0.004611:0.006939:0.013513:0.016024:0.014678:0.006939:0.004611:0.010843:0.006209:0.004611:0.006437:0.014518:0.011048:0.004611:0.006209:0.009108:0.008765:0.011459:0.011756:0.005547:0.009108:0.009405:0.005250:0.004611:0.007442:0.009131:0.011162:0.005250:0.005547:0.009108:0.008811:0.006209:0.009039:0.007670:0.018156:0.004497:0.004611:0.014586:0.007533:0.007944:0.008925:0.009724:0.004109
243:@0.806297:0.154815:0.824542:0.154815:0.824542:0.142937:0.806297:0.142937:0.006082:0.006082:0.006082
quality was confirmed by calculating plate Z-factor across all plates (mean=0.61; :@0.147059:0.183009:0.849368:0.183009:0.849368:0.162636:0.147059:0.162636:0.010706:0.011596:0.009405:0.005250:0.005273:0.006437:0.009724:0.006928:0.014723:0.009291:0.007670:0.006939:0.008994:0.010843:0.011756:0.005684:0.005684:0.007807:0.017485:0.009108:0.011391:0.006928:0.010843:0.009724:0.006939:0.009108:0.009405:0.005182:0.009108:0.011550:0.005430:0.008813:0.006437:0.005615:0.011459:0.009861:0.006928:0.011162:0.005433:0.008811:0.006209:0.009039:0.006939:0.012966:0.007533:0.006209:0.009291:0.009106:0.006209:0.010843:0.007807:0.006939:0.009291:0.008994:0.007442:0.010957:0.007533:0.007670:0.006939:0.009405:0.005387:0.005250:0.006928:0.011162:0.005433:0.008811:0.006209:0.009039:0.007670:0.006939:0.006939:0.017485:0.009291:0.009085:0.011756:0.011779:0.010432:0.004497:0.010432:0.010432:0.004497:0.004109
Ex-:@0.852130:0.183009:0.882353:0.183009:0.882353:0.161876:0.852130:0.161876:0.012692:0.010317:0.007213
tended Data Figure 5e:@0.147059:0.203588:0.341495:0.203588:0.341495:0.182455:0.147059:0.182455:0.006871:0.009268:0.012167:0.011961:0.009724:0.011870:0.003675:0.016527:0.009542:0.007053:0.009861:0.003675:0.011596:0.006209:0.010751:0.011893:0.008261:0.009473:0.003675:0.010911:0.009473
) and by the correlation of AUC between technical and biological :@0.341493:0.203588:0.886551:0.203588:0.886551:0.183215:0.341493:0.183215:0.006939:0.003766:0.009085:0.011596:0.011391:0.003766:0.010843:0.009724:0.003766:0.006620:0.011299:0.009039:0.003766:0.008994:0.010843:0.007807:0.007442:0.008948:0.005433:0.008811:0.006437:0.005547:0.010843:0.011756:0.003766:0.010843:0.006209:0.003766:0.013513:0.016024:0.014678:0.003766:0.011254:0.009131:0.006437:0.014518:0.009108:0.009039:0.011756:0.003766:0.006209:0.009108:0.008765:0.011459:0.011756:0.005547:0.009108:0.009405:0.005250:0.003766:0.009085:0.011596:0.011391:0.003766:0.010820:0.005547:0.010934:0.005182:0.011048:0.009861:0.005547:0.009108:0.009405:0.005250:0.004109
replicates (Pearson correlation=0.94, 0.87, respectively; :@0.147059:0.224167:0.610892:0.224167:0.610892:0.203794:0.147059:0.203794:0.007442:0.009131:0.011162:0.005250:0.005547:0.009108:0.008811:0.006209:0.009039:0.007670:0.004109:0.006939:0.011162:0.009288:0.009085:0.007624:0.007875:0.010843:0.011756:0.004109:0.008994:0.010843:0.007807:0.007442:0.008948:0.005433:0.008811:0.006437:0.005547:0.010843:0.011756:0.011779:0.010432:0.004497:0.010432:0.010432:0.004497:0.004109:0.010432:0.004497:0.010432:0.010432:0.004497:0.004109:0.007439:0.009039:0.007510:0.011505:0.009106:0.009108:0.006437:0.005547:0.009633:0.008948:0.005182:0.010181:0.004497:0.004109
Extended Data Figure 5c,d:@0.610893:0.224167:0.846394:0.224167:0.846394:0.203034:0.610893:0.203034:0.012692:0.010318:0.006871:0.009268:0.012167:0.011961:0.009722:0.011870:0.004018:0.016527:0.009542:0.007053:0.009861:0.004018:0.011596:0.006209:0.010751:0.011893:0.008263:0.009473:0.004018:0.010911:0.009199:0.005433:0.011870
). :@0.846393:0.224167:0.861938:0.224167:0.861938:0.203794:0.846393:0.203794:0.006939:0.004497:0.004109
Unsupervised hierarchical clustering based on platinum/taxane drug sensitivity divided :@0.147059:0.265324:0.886503:0.265324:0.886503:0.244951:0.147059:0.244951:0.014883:0.011619:0.007510:0.011071:0.011505:0.009039:0.008400:0.009838:0.005615:0.007873:0.009108:0.011391:0.004177:0.011459:0.005547:0.009039:0.007898:0.009085:0.007442:0.008765:0.011459:0.005547:0.009108:0.009405:0.005250:0.004177:0.008765:0.004908:0.011413:0.007512:0.006209:0.009039:0.007807:0.005615:0.011459:0.009861:0.004177:0.011117:0.009291:0.007875:0.009108:0.011391:0.004177:0.010843:0.011756:0.004177:0.011162:0.005433:0.008811:0.006437:0.005615:0.011391:0.011413:0.017645:0.007099:0.006549:0.009291:0.010089:0.009085:0.011598:0.009039:0.004177:0.011391:0.007967:0.011413:0.009861:0.004177:0.007873:0.009039:0.011619:0.007601:0.005273:0.006437:0.005547:0.009838:0.005273:0.006437:0.009724:0.004177:0.011391:0.005545:0.009838:0.005547:0.011322:0.009106:0.011391:0.004109
the organoids into two main clusters: sensitive lines that consisted primarily of HGS or-:@0.147059:0.285903:0.882353:0.285903:0.882353:0.265530:0.147059:0.265530:0.006620:0.011299:0.009039:0.004474:0.010843:0.007624:0.009861:0.009085:0.011596:0.010843:0.005547:0.011391:0.007670:0.004474:0.005615:0.011391:0.006209:0.011048:0.004474:0.006437:0.014518:0.011048:0.004474:0.017577:0.009085:0.005615:0.011756:0.004474:0.008765:0.004908:0.011413:0.007510:0.006209:0.009039:0.007624:0.007670:0.004497:0.004474:0.007875:0.009039:0.011619:0.007601:0.005273:0.006437:0.005547:0.009633:0.009039:0.004474:0.005250:0.005615:0.011596:0.009039:0.007670:0.004474:0.006620:0.011391:0.008811:0.006437:0.004474:0.008994:0.010843:0.011619:0.007601:0.005615:0.007510:0.006209:0.009108:0.011391:0.004474:0.011071:0.007807:0.005615:0.017577:0.009085:0.007807:0.005752:0.005182:0.009724:0.004474:0.010843:0.006209:0.004474:0.016412:0.015682:0.010112:0.004474:0.010843:0.007143:0.007533
ganoids and resistant lines that consisted primarily of non-HGS organoids (:@0.147059:0.306482:0.785686:0.306482:0.785686:0.286109:0.147059:0.286109:0.009861:0.009085:0.011596:0.010843:0.005547:0.011391:0.007670:0.004657:0.009085:0.011596:0.011391:0.004657:0.007442:0.009039:0.007601:0.005615:0.007510:0.006549:0.009085:0.011393:0.006437:0.004657:0.005250:0.005615:0.011596:0.009039:0.007670:0.004657:0.006620:0.011391:0.008811:0.006437:0.004657:0.008994:0.010843:0.011619:0.007601:0.005615:0.007512:0.006209:0.009106:0.011391:0.004657:0.011071:0.007807:0.005615:0.017577:0.009085:0.007807:0.005752:0.005182:0.009724:0.004657:0.010843:0.006209:0.004657:0.011596:0.010843:0.011756:0.007533:0.016412:0.015682:0.010112:0.004657:0.010843:0.007624:0.009861:0.009087:0.011596:0.010843:0.005547:0.011391:0.007670:0.004657:0.006939
Figure 6b:@0.785652:0.306482:0.870910:0.306482:0.870910:0.285349:0.785652:0.285349:0.011596:0.006209:0.010751:0.011893:0.008263:0.009473:0.004543:0.010911:0.011619
). :@0.870917:0.306482:0.886462:0.306482:0.886462:0.286109:0.870917:0.286109:0.006939:0.004497:0.004109
Notably, the HGS-1-R3 line, which was derived from ascites of recurrent disease, clini-:@0.147059:0.327060:0.882353:0.327060:0.882353:0.306687:0.147059:0.306687:0.015522:0.010820:0.006551:0.009108:0.010911:0.005182:0.007989:0.004497:0.005079:0.006620:0.011299:0.009039:0.005079:0.016412:0.015682:0.010112:0.007533:0.010432:0.007533:0.013376:0.010432:0.005079:0.005250:0.005615:0.011596:0.008743:0.004497:0.005079:0.014792:0.011459:0.005547:0.008765:0.011459:0.005079:0.014723:0.009291:0.007670:0.005079:0.011322:0.009039:0.007807:0.005547:0.009633:0.009108:0.011391:0.005079:0.006414:0.007442:0.010843:0.017645:0.005079:0.009291:0.007875:0.008994:0.005273:0.006209:0.009039:0.007670:0.005079:0.010843:0.006209:0.005079:0.007442:0.009108:0.009108:0.011413:0.007807:0.007442:0.009039:0.011391:0.006437:0.005079:0.011391:0.005615:0.007875:0.009288:0.009291:0.007875:0.008743:0.004497:0.005079:0.008765:0.005250:0.005615:0.011756:0.005615:0.007533
cally resistant to chemotherapy (:@0.147059:0.347639:0.416232:0.347639:0.416232:0.327266:0.147059:0.327266:0.009108:0.009405:0.005387:0.005182:0.009724:0.003401:0.007442:0.009039:0.007601:0.005615:0.007510:0.006551:0.009085:0.011391:0.006437:0.003401:0.006209:0.011048:0.003401:0.008765:0.011299:0.009039:0.017485:0.010820:0.006620:0.011299:0.009039:0.007898:0.008811:0.011094:0.009724:0.003401:0.006939
Supplementary Table 1:@0.416195:0.347639:0.618304:0.347639:0.618304:0.326506:0.416195:0.326506:0.010455:0.011893:0.011733:0.011779:0.005935:0.009268:0.018102:0.009268:0.012053:0.007053:0.009656:0.009359:0.009998:0.003310:0.011413:0.009679:0.011528:0.005935:0.009473:0.003310:0.010911
), clustered together with the re-:@0.618316:0.347639:0.882353:0.347639:0.882353:0.327266:0.618316:0.327266:0.006939:0.004497:0.003401:0.008765:0.004908:0.011413:0.007510:0.006209:0.009039:0.007442:0.009108:0.011391:0.003401:0.006209:0.011048:0.009656:0.009131:0.006620:0.011299:0.009039:0.007807:0.003401:0.014723:0.005273:0.006620:0.011459:0.003401:0.006620:0.011299:0.009039:0.003401:0.007442:0.008993:0.007533
sistant cluster. HGS-1 line, which was derived from the primary, chemotherapy- sensitive :@0.147059:0.368218:0.886368:0.368218:0.886368:0.347845:0.147059:0.347845:0.007601:0.005615:0.007510:0.006551:0.009085:0.011391:0.006437:0.003287:0.008765:0.004908:0.011413:0.007510:0.006209:0.009039:0.006255:0.004497:0.003287:0.016412:0.015682:0.010112:0.007533:0.010432:0.003287:0.005250:0.005615:0.011596:0.008743:0.004497:0.003287:0.014792:0.011459:0.005547:0.008765:0.011459:0.003287:0.014723:0.009291:0.007670:0.003287:0.011322:0.009039:0.007807:0.005547:0.009633:0.009108:0.011391:0.003287:0.006412:0.007442:0.010843:0.017645:0.003287:0.006620:0.011299:0.009039:0.003287:0.011071:0.007807:0.005615:0.017577:0.009085:0.008398:0.007992:0.004497:0.003287:0.008765:0.011299:0.009039:0.017485:0.010820:0.006620:0.011299:0.009039:0.007898:0.008811:0.011094:0.009724:0.007533:0.003287:0.007873:0.009039:0.011619:0.007601:0.005273:0.006437:0.005547:0.009633:0.009039:0.004109
tumor of the same patient clustered with the sensitive cluster (:@0.147059:0.388796:0.663923:0.388796:0.663923:0.368423:0.147059:0.368423:0.006163:0.011413:0.017485:0.010843:0.007807:0.004109:0.010843:0.006209:0.004109:0.006620:0.011299:0.009039:0.004109:0.007944:0.009085:0.017485:0.009039:0.004109:0.011368:0.008811:0.006437:0.005547:0.009039:0.011391:0.006437:0.004109:0.008765:0.004908:0.011413:0.007510:0.006209:0.009039:0.007442:0.009108:0.011391:0.004109:0.014723:0.005271:0.006620:0.011459:0.004109:0.006620:0.011299:0.009039:0.004109:0.007875:0.009039:0.011619:0.007601:0.005273:0.006437:0.005547:0.009633:0.009039:0.004109:0.008765:0.004908:0.011413:0.007510:0.006209:0.009039:0.007807:0.004109:0.006939
Figure 6a,b:@0.663922:0.388796:0.763949:0.388796:0.763949:0.367664:0.663922:0.367664:0.011596:0.006209:0.010751:0.011893:0.008263:0.009473:0.004018:0.010911:0.009861:0.005433:0.011619
). :@0.763948:0.388796:0.779493:0.388796:0.779493:0.368423:0.763948:0.368423:0.006939:0.004497:0.004109
Since the :@0.147059:0.429954:0.228482:0.429954:0.228482:0.409581:0.147059:0.409581:0.010112:0.005615:0.011596:0.008994:0.009039:0.004999:0.006620:0.011299:0.009039:0.004109
TP53:@0.229387:0.430423:0.277575:0.430423:0.277575:0.408401:0.229387:0.408401:0.013765:0.012646:0.010888:0.010888
 gene is mutated in the vast majority of OC, we tested whether nutlin3a :@0.277574:0.429954:0.886364:0.429954:0.886364:0.409581:0.277574:0.409581:0.004999:0.009656:0.009039:0.011596:0.009039:0.004999:0.005615:0.007670:0.004999:0.017280:0.011071:0.006551:0.008811:0.006209:0.009108:0.011391:0.004999:0.005615:0.011756:0.004999:0.006617:0.011302:0.009039:0.004999:0.009838:0.009291:0.007510:0.006437:0.004999:0.017577:0.008811:0.005341:0.010843:0.007807:0.005273:0.006437:0.009724:0.004999:0.010845:0.006209:0.004999:0.016778:0.014678:0.004497:0.004999:0.014518:0.009039:0.004999:0.006209:0.009039:0.007510:0.006209:0.009108:0.011391:0.004999:0.014789:0.011299:0.009131:0.006620:0.011299:0.009039:0.007807:0.004999:0.011391:0.011071:0.006620:0.005250:0.005615:0.011756:0.010432:0.009291:0.004109
can serve to rapidly distinguish between wild-type and mutated :@0.147059:0.450532:0.683212:0.450532:0.683212:0.430160:0.147059:0.430160:0.009108:0.009085:0.011756:0.004018:0.007873:0.009039:0.008400:0.009633:0.009039:0.004018:0.006209:0.011048:0.004018:0.007898:0.008811:0.011071:0.005547:0.011528:0.005182:0.009724:0.004018:0.011391:0.005615:0.007510:0.006437:0.005615:0.011459:0.009861:0.011413:0.005615:0.007556:0.011459:0.004018:0.011254:0.009131:0.006437:0.014518:0.009108:0.009039:0.011756:0.004018:0.014723:0.005752:0.005182:0.011391:0.007533:0.006437:0.009724:0.011505:0.009039:0.004018:0.009085:0.011596:0.011391:0.004018:0.017280:0.011071:0.006551:0.008811:0.006209:0.009108:0.011391:0.004109
TP53:@0.683069:0.451001:0.731257:0.451001:0.731257:0.428979:0.683069:0.428979:0.013765:0.012646:0.010888:0.010888
 OC organoids. In :@0.731256:0.450532:0.886476:0.450532:0.886476:0.430160:0.731256:0.430160:0.004018:0.016775:0.014678:0.004018:0.010843:0.007624:0.009861:0.009085:0.011596:0.010843:0.005547:0.011391:0.007670:0.004497:0.004018:0.006894:0.011756:0.004109
total, 16 organoid lines were tested (3 normal FT lines, one genetically modified FT clone :@0.147059:0.471111:0.886462:0.471111:0.886462:0.450738:0.147059:0.450738:0.006209:0.010820:0.006551:0.009405:0.004976:0.004497:0.003504:0.010432:0.010432:0.003502:0.010845:0.007624:0.009861:0.009085:0.011596:0.010843:0.005547:0.011391:0.003504:0.005250:0.005615:0.011596:0.009039:0.007670:0.003504:0.014518:0.009039:0.007442:0.009039:0.003504:0.006209:0.009039:0.007510:0.006209:0.009108:0.011391:0.003504:0.006939:0.010432:0.003504:0.011596:0.010843:0.007807:0.017577:0.009405:0.005250:0.003504:0.011276:0.013354:0.003504:0.005250:0.005615:0.011594:0.009039:0.007670:0.004497:0.003504:0.010843:0.011598:0.009039:0.003504:0.009656:0.009039:0.011596:0.009131:0.006437:0.005547:0.009106:0.009405:0.005387:0.005182:0.009724:0.003504:0.017485:0.011276:0.011391:0.005615:0.005684:0.005615:0.009108:0.011391:0.003504:0.011276:0.013354:0.003504:0.008765:0.005182:0.010843:0.011596:0.009039:0.004109
and 13 OC lines). As expected, all FT organoid lines were highly sensitive to nutlin3a :@0.147059:0.491690:0.886578:0.491690:0.886578:0.471317:0.147059:0.471317:0.009085:0.011596:0.011391:0.005958:0.010432:0.010432:0.005958:0.016778:0.014678:0.005958:0.005250:0.005615:0.011598:0.009039:0.007670:0.006939:0.004497:0.005958:0.014586:0.007670:0.005958:0.009108:0.010089:0.011505:0.009108:0.009108:0.006209:0.009106:0.011117:0.004497:0.005958:0.009405:0.005387:0.005250:0.005958:0.011276:0.013354:0.005958:0.010843:0.007624:0.009861:0.009085:0.011596:0.010843:0.005547:0.011391:0.005958:0.005250:0.005615:0.011596:0.009039:0.007670:0.005958:0.014518:0.009039:0.007442:0.009039:0.005958:0.011459:0.005615:0.009927:0.011573:0.005182:0.009724:0.005958:0.007875:0.009039:0.011619:0.007601:0.005273:0.006437:0.005547:0.009633:0.009039:0.005958:0.006211:0.011048:0.005958:0.011391:0.011071:0.006620:0.005250:0.005615:0.011756:0.010432:0.009291:0.004109
treatment whereas the genetically modified clone in which we knocked out the :@0.147059:0.512269:0.832065:0.512269:0.832065:0.491896:0.147059:0.491896:0.006437:0.007442:0.009291:0.008811:0.006437:0.017485:0.009039:0.011391:0.006437:0.006163:0.014792:0.011299:0.009039:0.007442:0.009288:0.009291:0.007670:0.006163:0.006620:0.011299:0.009039:0.006163:0.009656:0.009039:0.011596:0.009131:0.006437:0.005547:0.009108:0.009405:0.005387:0.005182:0.009724:0.006163:0.017485:0.011276:0.011391:0.005615:0.005684:0.005615:0.009108:0.011391:0.006163:0.008765:0.005182:0.010843:0.011596:0.009039:0.006163:0.005615:0.011756:0.006163:0.014792:0.011459:0.005547:0.008765:0.011459:0.006163:0.014518:0.009039:0.006163:0.010706:0.011598:0.011274:0.008765:0.010274:0.009106:0.011391:0.006163:0.010820:0.011071:0.006437:0.006163:0.006620:0.011299:0.009039:0.004109
TP53:@0.834166:0.512737:0.882353:0.512737:0.882353:0.490715:0.834166:0.490715:0.013765:0.012646:0.010888:0.010888
 :@0.882352:0.512269:0.886461:0.512269:0.886461:0.491896:0.882352:0.491896:0.004109
gene and the OC lines (with one exception) were resistant (:@0.147059:0.532847:0.653291:0.532847:0.653291:0.512474:0.147059:0.512474:0.009656:0.009039:0.011596:0.009039:0.005341:0.009085:0.011596:0.011391:0.005341:0.006620:0.011302:0.009039:0.005341:0.016778:0.014678:0.005341:0.005250:0.005615:0.011596:0.009039:0.007670:0.005341:0.006939:0.014723:0.005273:0.006620:0.011459:0.005341:0.010843:0.011596:0.009039:0.005341:0.009108:0.009884:0.008994:0.009131:0.011048:0.006437:0.005547:0.010843:0.011756:0.006939:0.005341:0.014518:0.009039:0.007442:0.009039:0.005341:0.007442:0.009039:0.007601:0.005615:0.007510:0.006551:0.009085:0.011391:0.006437:0.005341:0.006939
Figure 6c,d:@0.653209:0.532847:0.754021:0.532847:0.754021:0.511714:0.653209:0.511714:0.011596:0.006209:0.010751:0.011893:0.008263:0.009473:0.005214:0.010911:0.009199:0.005433:0.011870
). The only OC :@0.754022:0.532847:0.886486:0.532847:0.886486:0.512474:0.754022:0.512474:0.006939:0.004497:0.005341:0.011470:0.011311:0.009039:0.005341:0.010843:0.011870:0.005182:0.009724:0.005341:0.016778:0.014678:0.004109
line that was sensitive to nutlin3a, was LGS-1.3 and in this organoid, indeed no point :@0.147059:0.553426:0.886555:0.553426:0.886555:0.533053:0.147059:0.533053:0.005250:0.005615:0.011596:0.009039:0.005958:0.006620:0.011391:0.008811:0.006437:0.005958:0.014723:0.009291:0.007670:0.005958:0.007873:0.009039:0.011619:0.007604:0.005271:0.006437:0.005547:0.009635:0.009039:0.005958:0.006209:0.011048:0.005958:0.011391:0.011071:0.006620:0.005250:0.005615:0.011756:0.010432:0.009291:0.004497:0.005958:0.014723:0.009291:0.007670:0.005958:0.011528:0.015682:0.010112:0.007533:0.010432:0.004497:0.010432:0.005958:0.009085:0.011596:0.011391:0.005958:0.005615:0.011756:0.005958:0.006620:0.011459:0.005615:0.007670:0.005958:0.010843:0.007624:0.009861:0.009085:0.011596:0.010845:0.005545:0.011117:0.004497:0.005958:0.005615:0.011596:0.011322:0.009108:0.009106:0.011391:0.005958:0.011598:0.011048:0.005958:0.011505:0.010843:0.005615:0.011391:0.006437:0.004109
mutation in the :@0.147059:0.574005:0.282011:0.574005:0.282011:0.553632:0.147059:0.553632:0.017280:0.011071:0.006551:0.008811:0.006437:0.005547:0.010843:0.011756:0.004109:0.005615:0.011756:0.004109:0.006620:0.011299:0.009039:0.004109
TP53:@0.282010:0.574474:0.330197:0.574474:0.330197:0.552451:0.282010:0.552451:0.013765:0.012646:0.010888:0.010888
 gene was identified (:@0.330196:0.574005:0.505732:0.574005:0.505732:0.553632:0.330196:0.553632:0.004109:0.009656:0.009039:0.011596:0.009039:0.004109:0.014723:0.009291:0.007670:0.004109:0.005547:0.011322:0.009039:0.011391:0.006437:0.005615:0.005684:0.005615:0.009106:0.011391:0.004109:0.006939
Supplementary Table 7:@0.505732:0.574005:0.709256:0.574005:0.709256:0.552872:0.505732:0.552872:0.010455:0.011893:0.011733:0.011779:0.005935:0.009268:0.018102:0.009268:0.012053:0.007053:0.009656:0.009359:0.009998:0.004018:0.011413:0.009679:0.011528:0.005935:0.009473:0.004018:0.010911
). :@0.709254:0.574005:0.724799:0.574005:0.724799:0.553632:0.709254:0.553632:0.006939:0.004497:0.004109
Drug-screening assays demonstrated differential drug responses of individual organoid :@0.147059:0.594583:0.886439:0.594583:0.886439:0.574210:0.147059:0.574210:0.016024:0.007967:0.011413:0.009861:0.007533:0.007873:0.008994:0.007442:0.009108:0.009039:0.011756:0.005615:0.011459:0.009861:0.004520:0.009291:0.007531:0.007944:0.008925:0.009724:0.007670:0.004520:0.011322:0.009039:0.017485:0.010843:0.011619:0.007510:0.006437:0.007898:0.008811:0.006209:0.009108:0.011391:0.004520:0.011391:0.005615:0.005969:0.005787:0.009039:0.007442:0.009039:0.011391:0.006437:0.005798:0.009405:0.005250:0.004520:0.011391:0.007967:0.011413:0.009861:0.004520:0.007442:0.009039:0.007510:0.011505:0.010843:0.011619:0.007875:0.009039:0.007670:0.004520:0.010843:0.006209:0.004520:0.005615:0.011596:0.011391:0.005547:0.009838:0.005547:0.011048:0.011596:0.009405:0.005250:0.004520:0.010843:0.007624:0.009861:0.009085:0.011598:0.010843:0.005547:0.011391:0.004109
lines (:@0.147059:0.615162:0.197437:0.615162:0.197437:0.594789:0.147059:0.594789:0.005250:0.005615:0.011596:0.009039:0.007670:0.004269:0.006939
Figure 6a–e:@0.197441:0.615162:0.301417:0.615162:0.301417:0.594029:0.197441:0.594029:0.011596:0.006209:0.010751:0.011893:0.008263:0.009473:0.004177:0.010911:0.009861:0.011368:0.009473
). For example, HGS-3.1 organoid line was highly sensitive to gemcit-:@0.301417:0.615162:0.882353:0.615162:0.882353:0.594789:0.301417:0.594789:0.006939:0.004497:0.004269:0.010683:0.010843:0.007807:0.004269:0.009106:0.010089:0.009085:0.017280:0.011162:0.005182:0.008745:0.004497:0.004269:0.016412:0.015682:0.010112:0.007533:0.010432:0.004497:0.010432:0.004269:0.010843:0.007624:0.009861:0.009085:0.011596:0.010843:0.005547:0.011391:0.004269:0.005250:0.005615:0.011596:0.009039:0.004269:0.014723:0.009291:0.007670:0.004269:0.011459:0.005615:0.009930:0.011573:0.005182:0.009724:0.004269:0.007875:0.009039:0.011619:0.007601:0.005273:0.006437:0.005547:0.009633:0.009039:0.004269:0.006209:0.011048:0.004269:0.009656:0.009039:0.017485:0.008994:0.005273:0.006477:0.007533
abine, adavosertib, carboplatin and paclitaxel and resistant to drugs that target the PI3K/ :@0.147059:0.635741:0.886555:0.635741:0.886555:0.615368:0.147059:0.615368:0.009108:0.010820:0.005615:0.011596:0.008743:0.004497:0.003835:0.009291:0.011573:0.008925:0.009633:0.010957:0.007875:0.009039:0.007964:0.006437:0.005547:0.010249:0.004497:0.003835:0.009108:0.009085:0.007715:0.011254:0.010820:0.011160:0.005433:0.008813:0.006437:0.005615:0.011756:0.003835:0.009085:0.011596:0.011391:0.003835:0.011368:0.009291:0.008765:0.005250:0.005271:0.006551:0.009291:0.009884:0.008948:0.005250:0.003835:0.009085:0.011596:0.011391:0.003835:0.007442:0.009039:0.007601:0.005615:0.007510:0.006551:0.009085:0.011391:0.006437:0.003835:0.006211:0.011048:0.003835:0.011391:0.007967:0.011413:0.009724:0.007670:0.003835:0.006620:0.011391:0.008813:0.006437:0.003835:0.006551:0.009085:0.007624:0.009656:0.009131:0.006437:0.003835:0.006620:0.011299:0.009039:0.003835:0.011664:0.007259:0.010432:0.014541:0.007099:0.004109
AKT/mTOR pathway, whereas HGS-23 line demonstrated the opposite drug sensitivity :@0.147059:0.656319:0.886391:0.656319:0.886391:0.635947:0.147059:0.635947:0.014929:0.014541:0.013354:0.007099:0.015659:0.013057:0.016047:0.013376:0.004428:0.011368:0.008811:0.006620:0.011071:0.014723:0.008925:0.007989:0.004497:0.004428:0.014792:0.011299:0.009039:0.007442:0.009291:0.009291:0.007670:0.004428:0.016412:0.015682:0.010112:0.007533:0.010432:0.010432:0.004428:0.005250:0.005615:0.011596:0.009039:0.004428:0.011322:0.009039:0.017485:0.010843:0.011619:0.007510:0.006437:0.007898:0.008811:0.006209:0.009108:0.011391:0.004428:0.006620:0.011299:0.009039:0.004428:0.010820:0.011046:0.011505:0.010957:0.007601:0.005273:0.006209:0.009039:0.004428:0.011391:0.007967:0.011413:0.009861:0.004428:0.007873:0.009039:0.011619:0.007604:0.005271:0.006437:0.005547:0.009838:0.005273:0.006437:0.009724:0.004109
pattern (:@0.147059:0.676898:0.219260:0.676898:0.219260:0.656525:0.147059:0.656525:0.011368:0.008811:0.006163:0.006209:0.009039:0.007807:0.011756:0.004109:0.006939
Figure 6a–d:@0.219259:0.676898:0.325472:0.676898:0.325472:0.655765:0.219259:0.655765:0.011596:0.006209:0.010751:0.011893:0.008263:0.009473:0.004018:0.010911:0.009861:0.011368:0.011870
). :@0.325470:0.676898:0.341015:0.676898:0.341015:0.656525:0.325470:0.656525:0.006939:0.004497:0.004109
Homologous recombination-deficient cells have been shown to be sensitive to PARP :@0.147059:0.718056:0.886532:0.718056:0.886532:0.697683:0.147059:0.697683:0.016207:0.010843:0.017485:0.010934:0.005182:0.011048:0.009656:0.010820:0.011413:0.007670:0.006802:0.007442:0.009108:0.008994:0.010843:0.017394:0.010820:0.005615:0.011687:0.008811:0.006437:0.005547:0.010843:0.011756:0.007533:0.011322:0.009039:0.005684:0.005615:0.008994:0.005547:0.009039:0.011391:0.006437:0.006802:0.008994:0.008948:0.005387:0.005250:0.007670:0.006802:0.011391:0.008925:0.009633:0.009039:0.006802:0.011254:0.009108:0.009039:0.011756:0.006802:0.007556:0.011299:0.010866:0.014723:0.011756:0.006802:0.006209:0.011048:0.006802:0.011254:0.009039:0.006802:0.007873:0.009039:0.011621:0.007601:0.005273:0.006437:0.005547:0.009633:0.009039:0.006802:0.006211:0.011048:0.006802:0.010247:0.014929:0.013376:0.012167:0.004109
inhibitors:@0.147059:0.738634:0.229988:0.738634:0.229988:0.718261:0.147059:0.718261:0.005615:0.011870:0.011459:0.005547:0.010820:0.005273:0.006209:0.010843:0.007624:0.007670
244,245:@0.229988:0.731018:0.269100:0.731018:0.269100:0.719141:0.229988:0.719141:0.006082:0.006082:0.006082:0.002622:0.006082:0.006082:0.006082
. To determine whether this correlation is also present in OC organoids, :@0.269098:0.738634:0.886426:0.738634:0.886426:0.718261:0.269098:0.718261:0.004497:0.005296:0.010868:0.011048:0.005296:0.011322:0.009131:0.006209:0.009039:0.007807:0.017645:0.005615:0.011596:0.009039:0.005296:0.014792:0.011299:0.009131:0.006620:0.011299:0.009039:0.007807:0.005296:0.006617:0.011459:0.005615:0.007670:0.005296:0.008994:0.010843:0.007807:0.007442:0.008948:0.005433:0.008811:0.006437:0.005547:0.010843:0.011756:0.005296:0.005615:0.007670:0.005296:0.009405:0.005250:0.007875:0.011048:0.005296:0.011071:0.007442:0.009039:0.007875:0.009039:0.011391:0.006437:0.005296:0.005615:0.011756:0.005296:0.016778:0.014678:0.005296:0.010843:0.007624:0.009861:0.009085:0.011596:0.010845:0.005545:0.011391:0.007670:0.004497:0.004109
a subset of organoid lines with differential responses to niraparib (:@0.147059:0.759213:0.712522:0.759213:0.712522:0.738840:0.147059:0.738840:0.009291:0.005364:0.007510:0.011345:0.010934:0.007875:0.009131:0.006437:0.005364:0.010843:0.006209:0.005364:0.010843:0.007624:0.009861:0.009085:0.011596:0.010843:0.005547:0.011391:0.005364:0.005250:0.005615:0.011596:0.009039:0.007670:0.005364:0.014723:0.005273:0.006620:0.011459:0.005364:0.011391:0.005615:0.005969:0.005787:0.009039:0.007442:0.009039:0.011391:0.006437:0.005796:0.009405:0.005250:0.005364:0.007442:0.009039:0.007510:0.011505:0.010843:0.011619:0.007875:0.009039:0.007670:0.005364:0.006209:0.011048:0.005364:0.011756:0.005615:0.007898:0.008811:0.011368:0.009085:0.007807:0.005547:0.011025:0.005364:0.006939
Figure 6e:@0.712473:0.759213:0.796293:0.759213:0.796293:0.738080:0.712473:0.738080:0.011596:0.006209:0.010751:0.011893:0.008263:0.009473:0.005250:0.010911:0.009473
) was test-:@0.796283:0.759213:0.882353:0.759213:0.882353:0.738840:0.796283:0.738840:0.006939:0.005364:0.014723:0.009291:0.007670:0.005364:0.006209:0.009039:0.007510:0.006427:0.007533
ed for homologous recombination by using the recombination capacity (RECAP) test, :@0.147059:0.779792:0.886505:0.779792:0.886505:0.759419:0.147059:0.759419:0.009108:0.011391:0.005593:0.006026:0.010843:0.007807:0.005593:0.011299:0.010843:0.017485:0.010934:0.005182:0.011048:0.009656:0.010820:0.011413:0.007670:0.005593:0.007442:0.009108:0.008994:0.010843:0.017394:0.010820:0.005615:0.011687:0.008811:0.006437:0.005547:0.010843:0.011756:0.005593:0.010843:0.009724:0.005593:0.011413:0.007601:0.005615:0.011459:0.009861:0.005593:0.006620:0.011299:0.009039:0.005593:0.007442:0.009108:0.008994:0.010843:0.017394:0.010820:0.005615:0.011687:0.008811:0.006437:0.005547:0.010843:0.011756:0.005593:0.009108:0.008811:0.011365:0.009291:0.008994:0.005271:0.006437:0.009724:0.005593:0.006939:0.013376:0.012098:0.014678:0.014929:0.012167:0.006939:0.005593:0.006209:0.009039:0.007510:0.006437:0.004497:0.004109
which assesses homologous recombination capacity using accumulation of RAD51 :@0.147059:0.800370:0.886507:0.800370:0.886507:0.779998:0.147059:0.779998:0.014792:0.011459:0.005547:0.008765:0.011459:0.008971:0.009291:0.007533:0.007875:0.009039:0.007533:0.007875:0.009039:0.007670:0.008971:0.011299:0.010843:0.017485:0.010934:0.005182:0.011048:0.009656:0.010820:0.011413:0.007670:0.008971:0.007442:0.009108:0.008994:0.010843:0.017394:0.010820:0.005615:0.011687:0.008811:0.006437:0.005547:0.010843:0.011756:0.008971:0.009108:0.008811:0.011368:0.009291:0.008994:0.005273:0.006437:0.009724:0.008971:0.011413:0.007601:0.005615:0.011459:0.009861:0.008971:0.009291:0.008994:0.009108:0.011413:0.017280:0.011550:0.005430:0.008811:0.006437:0.005549:0.010840:0.011756:0.008971:0.010843:0.006209:0.008971:0.013650:0.014929:0.016139:0.010432:0.010432:0.004109
protein at sites of DNA double-strand breaks . Organoids were irradiated with 5 Gy :@0.147059:0.820949:0.886409:0.820949:0.886409:0.800576:0.147059:0.800576:0.011071:0.007442:0.010820:0.006209:0.009039:0.005615:0.011756:0.006163:0.008811:0.006437:0.006163:0.007601:0.005273:0.006209:0.009039:0.007670:0.006163:0.010843:0.006209:0.006163:0.015773:0.015408:0.014929:0.006163:0.011322:0.010820:0.011345:0.010911:0.005182:0.009039:0.007533:0.007510:0.006437:0.007898:0.009085:0.011596:0.011391:0.006163:0.010820:0.007442:0.009291:0.009405:0.010523:0.007670:0.018298:0.004497:0.006163:0.016298:0.007624:0.009861:0.009085:0.011596:0.010843:0.005547:0.011391:0.007670:0.006163:0.014518:0.009039:0.007442:0.009039:0.006163:0.005615:0.007807:0.007898:0.009291:0.011391:0.005796:0.008811:0.006211:0.009108:0.011391:0.006163:0.014723:0.005273:0.006620:0.011459:0.006163:0.010432:0.006163:0.015614:0.009724:0.004109
246:@0.535464:0.813333:0.553710:0.813333:0.553710:0.801456:0.535464:0.801456:0.006082:0.006082:0.006082
X-rays, recovered for two hours, fixed and stained with antibodies against RAD51 and :@0.147059:0.841528:0.886462:0.841528:0.886462:0.821155:0.147059:0.821155:0.014107:0.007533:0.007898:0.008925:0.009724:0.007670:0.004497:0.005296:0.007442:0.009108:0.008994:0.010866:0.009633:0.009039:0.007442:0.009108:0.011391:0.005296:0.006024:0.010845:0.007807:0.005296:0.006437:0.014516:0.011048:0.005296:0.011299:0.010820:0.011413:0.007624:0.007670:0.004497:0.005296:0.005684:0.005684:0.009882:0.009108:0.011391:0.005296:0.009085:0.011598:0.011391:0.005296:0.007510:0.006551:0.009085:0.005615:0.011596:0.009108:0.011391:0.005296:0.014723:0.005273:0.006620:0.011459:0.005296:0.009085:0.011391:0.006437:0.005547:0.011254:0.011276:0.011391:0.005547:0.009039:0.007670:0.005296:0.009199:0.009861:0.009085:0.005615:0.011619:0.007510:0.006437:0.005296:0.013650:0.014929:0.016139:0.010432:0.010432:0.005296:0.009085:0.011596:0.011391:0.004109
geminin (a marker for S/G2 phases of the cell cycle). The percentage of geminin+ cells :@0.147059:0.862107:0.886416:0.862107:0.886416:0.841734:0.147059:0.841734:0.009656:0.009039:0.017645:0.005615:0.011756:0.005615:0.011756:0.005456:0.006939:0.009291:0.005456:0.017579:0.009083:0.007604:0.010272:0.009039:0.007807:0.005456:0.006026:0.010843:0.007807:0.005456:0.010112:0.007099:0.015682:0.010432:0.005456:0.011165:0.011391:0.009291:0.007873:0.009039:0.007670:0.005456:0.010843:0.006209:0.005456:0.006620:0.011299:0.009039:0.005456:0.008994:0.008948:0.005385:0.005250:0.005456:0.009382:0.009519:0.008765:0.005182:0.009039:0.006939:0.004497:0.005456:0.011470:0.011311:0.009039:0.005456:0.011502:0.009039:0.007442:0.008994:0.009039:0.011391:0.006551:0.009199:0.009656:0.009039:0.005456:0.010843:0.006209:0.005456:0.009656:0.009039:0.017645:0.005615:0.011756:0.005615:0.011756:0.011779:0.005456:0.008994:0.008948:0.005387:0.005250:0.007670:0.004109
with RAD51 foci was scored blinded for sensitivity to niraparib. Organoids with a low :@0.147059:0.882685:0.886576:0.882685:0.886576:0.862312:0.147059:0.862312:0.014723:0.005273:0.006620:0.011459:0.005387:0.013650:0.014929:0.016139:0.010432:0.010432:0.005387:0.006026:0.011274:0.008994:0.005615:0.005387:0.014723:0.009291:0.007670:0.005387:0.007875:0.008994:0.010843:0.007442:0.009108:0.011391:0.005387:0.010911:0.005250:0.005615:0.011596:0.011322:0.009108:0.011391:0.005387:0.006026:0.010843:0.007807:0.005387:0.007875:0.009039:0.011619:0.007601:0.005273:0.006437:0.005547:0.009838:0.005273:0.006437:0.009724:0.005387:0.006209:0.011048:0.005387:0.011756:0.005615:0.007898:0.008811:0.011368:0.009085:0.007807:0.005547:0.010249:0.004497:0.005387:0.016298:0.007624:0.009861:0.009085:0.011596:0.010843:0.005547:0.011391:0.007670:0.005387:0.014723:0.005273:0.006620:0.011459:0.005387:0.009291:0.005387:0.005182:0.010866:0.014723:0.004109
percentage of geminin+ cells with RAD51 foci were more sensitive to niraparib com-:@0.147059:0.903264:0.882353:0.903264:0.882353:0.882891:0.147059:0.882891:0.011505:0.009039:0.007442:0.008994:0.009039:0.011391:0.006551:0.009199:0.009656:0.009039:0.006140:0.010843:0.006209:0.006140:0.009656:0.009039:0.017645:0.005615:0.011756:0.005615:0.011756:0.011779:0.006140:0.008994:0.008948:0.005387:0.005250:0.007670:0.006140:0.014723:0.005273:0.006620:0.011459:0.006140:0.013650:0.014929:0.016139:0.010432:0.010432:0.006140:0.006026:0.011274:0.008994:0.005615:0.006140:0.014518:0.009039:0.007442:0.009039:0.006140:0.017485:0.010843:0.007442:0.009039:0.006140:0.007875:0.009039:0.011619:0.007601:0.005273:0.006437:0.005547:0.009633:0.009039:0.006140:0.006209:0.011048:0.006140:0.011756:0.005615:0.007898:0.008811:0.011368:0.009085:0.007807:0.005547:0.011025:0.006140:0.008994:0.010840:0.017579:0.007533